Results from a Prospective Observational Study of Men with Premature Ejaculation Treated with Dapoxetine or Alternative Care: The PAUSE Study

Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE). Its safety was established in a thorough clinical development program. To characterize the safety profile of dapoxetine in PE treatment and to r...

Full description

Saved in:

Bibliographic Details
Published in:	European urology Vol. 65; no. 4; pp. 733 - 739
Main Authors:	Mirone, Vincenzo, Arcaniolo, Davide, Rivas, David, Bull, Scott, Aquilina, Joseph W., Verze, Paolo
Format:	Journal Article
Language:	English
Published:	Kidlington Elsevier B.V 01.04.2014 Elsevier
Subjects:	Adolescent Adult Aged Aged, 80 and over Benzylamines - therapeutic use Biological and medical sciences Cardiovascular events Complementary Therapies Dapoxetine Gynecology. Andrology. Obstetrics Humans Male Male genital diseases Medical sciences Middle Aged Naphthalenes - therapeutic use Nephrology. Urinary tract diseases Non tumoral diseases Premature Ejaculation - therapy Prospective Studies Safety Selective Serotonin Reuptake Inhibitors - therapeutic use Syncope Urology Young Adult Cardiovascular events Safety Syncope Dapoxetine Human Nervous system diseases Nephrology Psychotropic Toxicity Consciousness impairment Sexual dysfunction Male Cardiovascular disease Care Urology Premature ejaculation Prospective Treatment Ejaculation disorders Adult Antidepressant agent Neurological disorder Male genital diseases
ISSN:	0302-2838, 1873-7560, 1873-7560
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!